Keyphrases
Carboxylated multi-walled Carbon Nanotubes
100%
Older Adults
100%
Multi-walled Carbon Nanotubes (MWCNTs)
100%
Monolithic Capillary Column
100%
Racemic
100%
Topical Application
100%
Enantioseparation
100%
Levodopa
100%
Carbon Encapsulation
100%
Lipase
100%
High-performance Liquid Chromatography
100%
Retinal Function
100%
Organic Polymer
100%
Chiral Selector
100%
Levodopa-carbidopa
75%
Eye Drops
75%
NanoLC
66%
Multifocal Electroretinogram (mfERG)
50%
Clinically Significant
50%
Ocular Disorders
50%
Retinal Structure
50%
Normal-phase HPLC
33%
Monolithic Polymer
33%
Functionalized multi-walled Carbon Nanotubes
33%
Lipase Immobilization
33%
Reversed-phase HPLC
33%
Chiral Separation
33%
Capillary
33%
Racemic Drugs
33%
Monolith
33%
HPLC Separation
33%
Enantioselectivity
33%
Retinal Thickness Map
25%
Retinal Thinning
25%
Regional Frequency
25%
Frequency Doubling Perimetry
25%
Phase I Trial
25%
Short-term Use
25%
Dopaminergic System
25%
Placebo
25%
Myopia
25%
Dopamine System
25%
Translational Relevance
25%
End of Treatment
25%
Dysregulated
25%
Dopamine
25%
Retinal Thickness
25%
Consecutive Days
25%
Dysregulation
25%
Pharmacokinetic Analysis
25%
Healthy Males
25%
Normal Vision
25%
High Dose
25%
Fellow Eye
25%
Therapeutic Solutions
25%
Optical Coherence Tomography
25%
Visual Acuity
25%
Regional Analysis
25%
Ocular Safety
10%
Pupillary Reflex
10%
Nicotinic Receptors
10%
Temporary Reduction
10%
Medicine and Dentistry
Topical Drug Administration
100%
Levodopa
100%
Low Drug Dose
75%
Carbidopa/Levodopa
75%
Eye Disease
50%
Nicotinic Receptor
33%
Pupillary Reflex
33%
Optical Coherence Tomography
25%
Visual Field Test
25%
Dopaminergic System
25%
Pharmacokinetic
25%
Drug Megadose
25%
Placebo
25%
Phase I Trials
25%
Visual Acuity
25%
Pharmacology, Toxicology and Pharmaceutical Science
Levodopa
100%
Carbidopa Plus Levodopa
75%
Mole (Insectivora)
50%
Eye Disease
50%
Leporidae
25%
Phase I Trials
25%
Placebo
25%
Pharmacokinetic
25%
Dopamine Receptor Stimulating Agent
25%
Nicotinic Receptor
20%